Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Docetaxel, usually administered according to maximum tolerated dose (MTD), can inhibit endothelial cell proliferation at low nanomolar concentrations. Docetaxel may exert antiangiogenic effects if dosed so plasma levels are maintained at low nanomolar concentrations over a prolonged time. We evaluated metronomic and MTD-based dosing of docetaxel with and without vandetanib, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity, in a head and neck xenograft model. A murine physiologically based pharmacokinetic model was modified to predict docetaxel distribution following i.p. administration to design dosing regimens that target prespecified plasma concentrations, for antiendothelial effects (metronomic), or exposure, to mimic 30 mg/m2 (weekly/MTD) docetaxel in humans. Animals were treated for 28 days with 1 mg/kg/d (DTX1) or 6 mg/kg q4d (DTX6) docetaxel with or without vandetanib (15 mg/kg/d p.o.) in mice bearing UMSCC2 tumor xenografts. The DTX1 dosing scheme was adjusted to treatment for 10 days followed by 9 days off due to severe gastrointestinal toxicity. All treatment groups significantly reduced tumor volume, tumor proliferation (Ki-67), and tumor endothelial cell proliferation (Ki-67/von Willebrand factor) compared with control. Addition of vandetanib to docetaxel treatment significantly enhanced tumor growth inhibition over single-agent therapy. A positive correlation of tumor endothelial cell proliferation with tumor growth rates demonstrates vandetanib and docetaxel antiangiogenic effects. Due to the morbidity observed with DTX1 treatment, it is difficult to clearly ascertain if metronomic schedules will be effective for treatment. Docetaxel with vandetanib is effective in treating UMSCC2 xenografts at concentrations relevant to exposures in humans.
Bradshaw-Pierce
Erica L
EL
Division of Medical Oncology, School of Medicine, University of Colorado Health Sciences Center, 12801 East 17th Avenue, Room L18-8401G, P.O. Box 6511, MS 8117, Aurora, CO 80045, USA. Erica.Pierce@uchsc.edu
Steinhauer
Courtney A
CA
Raben
David
D
Gustafson
Daniel L
DL
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003198:Computer Simulation; D000077143:Docetaxel; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D010880:Piperidines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
D010880:Piperidines; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; C452423:vandetanib
Int J Cancer. 2003 Mar 10;104(1):121-9
12532428
Neoplasia. 2007 Dec;9(12):1066-77
18084614
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4349-54
11917134
Clin Cancer Res. 2004 Jan 15;10(2):784-93
14760102
J Med Chem. 1999 Dec 30;42(26):5369-89
10639280
Jpn J Clin Oncol. 2003 Jun;33(6):297-301
12913084
Mol Cancer Ther. 2002 Nov;1(13):1191-200
12479700
Clin Cancer Res. 2003 Apr;9(4):1546-56
12684431
Drugs. 2005;65(17):2513-31
16296875
Cancer Metastasis Rev. 2005 Jan;24(1):47-69
15785872
J Theor Biol. 1976 Jul 7;59(2):253-76
957690
J Pharmacol Exp Ther. 2006 Aug;318(2):872-80
16644900
Science. 2000 Aug 18;289(5482):1197-202
10947988
Eur J Cancer. 2005 May;41(8):1117-26
15911234
Clin Cancer Res. 2007 Nov 1;13(21):6450-8
17975157
J Clin Oncol. 2006 Jun 10;24(17):2666-72
16763281
Lung Cancer. 2005 Dec;50S2:S3-S8
16551520
Am J Pathol. 2002 Sep;161(3):929-38
12213721
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
11597399
J Med Chem. 1991 Mar;34(3):992-8
1672159
Nat Rev Cancer. 2005 May;5(5):341-54
15864276
Clin Cancer Res. 2004 Mar 15;10(6):2179-89
15041739
Cancer Chemother Pharmacol. 1979;2(2):85-94
93986
Br J Cancer. 2005 Jul 25;93(2):173-7
16012521
Clin Cancer Res. 2004 Mar 15;10(6):1976-83
15041715
Mol Pharmacol. 1974 Mar;10(2):235-47
4212316
Oncologist. 2004;9 Suppl 1:2-10
15178810
J Clin Oncol. 2007 Sep 20;25(27):4270-7
17878479
Cancer Res. 2002 Aug 15;62(16):4645-55
12183421
Clin Cancer Res. 2006 Dec 1;12(23):7099-107
17145834
Clin Cancer Res. 2004 Dec 15;10(24):8587-93
15623642
Ann Oncol. 2005 Aug;16(8):1391-7
15905307
J Immunol Methods. 2000 Oct 20;244(1-2):205-15
11033033
Cancer Res. 2001 Apr 15;61(8):3369-72
11309294
Eur J Cancer. 1996 Dec;32A(14):2413-22
9059329
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
Clin Cancer Res. 2007 May 1;13(9):2768-76
17473210
J Med Chem. 2002 Mar 14;45(6):1300-12
11881999
Cancer J. 2006 Jan-Feb;12(1):63-8
16613664
J Biol Chem. 1998 Nov 13;273(46):30336-43
9804796
Breast Cancer Res Treat. 2003 Jun;79(3):287-99
12846413
Clin Cancer Res. 2005 Aug 1;11(15):5639-44
16061883
Invest New Drugs. 1995;13(1):1-11
7499102
Nat Med. 2003 Jun;9(6):685-93
12778167
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544